# A Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset Seizures

> **NCT01777139** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 30 (actual)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** Retigabine IR

## Key facts

- **NCT ID:** NCT01777139
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04-11
- **Primary completion:** 2016-12-14
- **Final completion:** 2017-09-13
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2020-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01777139

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01777139, "A Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset Seizures". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT01777139. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*